BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CTX310 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CTX310\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07491172-1098@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:CTX310: Phase 1 readout est. (NCT07491172)
DESCRIPTION:CTX310\, phase 1\, Atherosclerotic Cardiovascular Disease.\nStu
 dy: A Safety and Tolerability Trial Evaluating CTX310 in Participants With
  Refractory Dyslipidemias\nEstimated primary completion: June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ctx310#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07491172
URL:https://assetmemo.bio/drug/ctx310#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
